Dejan Jakimovski

Dr. Dejan Jakimovski

Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2019 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
CVCaila B. Vaughn
Caila B. Vaughn
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
KKKatelyn S. Kavak
Katelyn S. Kavak
MRMurali Ramanathan
Murali Ramanathan
RBRalph H. B. Benedict
Ralph H. B. Benedict
Bianca Weinstock-GuttmanBianca Weinstock-Guttman
Bianca Weinstock-Guttman

8 January 2018 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
CKChanna Kolb
Channa Kolb
MRMurali Ramanathan
Murali Ramanathan
RZRobert Zivadinov
Robert Zivadinov
Bianca Weinstock-GuttmanBianca Weinstock-Guttman
Bianca Weinstock-Guttman
Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.

13 May 2016 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
RZRobert Zivadinov
Robert Zivadinov
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
SGSirin Gandhi
Sirin Gandhi
RARahil Ahmed
Rahil Ahmed
MDMichael G. Dwyer
Michael G. Dwyer
Niels BergslandNiels Bergsland
Niels Bergsland
Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.

1 January 2019 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
RZRobert Zivadinov
Robert Zivadinov
YGYi Guan
Yi Guan
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
MRMurali Ramanathan
Murali Ramanathan
BWBianca Weinstock-Guttman
Bianca Weinstock-Guttman
Multiple sclerosis (MS) is a disease of the central nervous system characterized by inflammation, demyelination, and neuronal damage. Environmental and genetic factors are associated with the risk of developing MS, but the exact cause still remains unidentified. Epstein-Barr virus (EBV), vitamin D, and smoking are among the most well-established environmental risk factors in MS. Infectious mononucleosis, which is caused by delayed primary EBV infection, increases the risk of developing MS. EBV may also contribute to MS pathogenesis indirectly by activating silent human endogenous retrovirus-W. The emerging B-cell depleting therapies, particularly anti-CD20 agents such as rituximab, ocrelizumab, as well as the fully human ofatumumab, have shown promising clinical and magnetic resonance imaging benefit. One potential effect of these therapies is the depletion of memory B-cells, the primary reservoir site where EBV latency occurs. In addition, EBV potentially interacts with both genetic and other environmental factors to increase susceptibility and disease severity of MS. This review examines the role of EBV in MS pathophysiology and summarizes the recent clinical and radiological findings, with a focus on B-cells and in vivo imaging. Addressing the potential link between EBV and MS allows the better understanding of MS pathogenesis and helps to identify additional disease biomarkers that may be responsive to B-cell depleting intervention.

15 October 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
RZRobert Zivadinov
Robert Zivadinov
MRMurali Ramanthan
Murali Ramanthan
JHJesper Hagemeier
Jesper Hagemeier
BWBianca Weinstock-Guttman
Bianca Weinstock-Guttman
RBRalph Hb Benedict
Ralph Hb Benedict
A limited number of studies investigated associations between serum neurofilament light chain (sNfL) and cognition in persons with multiple sclerosis (PwMS). To assess cross-sectional and longitudinal associations between sNfL levels, clinical, and cognitive performance in PwMS and age-matched healthy controls (HCs). One hundred twenty-seven PwMS (85 relapsing–remitting MS/42 progressive MS), 20 clinically isolated syndrome patients, and 52 HCs were followed for 5 years. sNfL levels were measured using the single-molecule array (Simoa) assay and quantified in picograms per milliliter. Expanded Disability Status Scale (EDSS), walking, and manual dexterity tests were obtained. At follow-up, Brief International Cognitive Assessment for MS (BICAMS) was utilized. Cognitively impaired (CI) status was derived using HC-based z-scores. Age-, sex-, and education-adjusted analysis of covariance (ANCOVA) and regression models were used. Multiple comparison–adjusted values of q < 0.05 were considered significant. In PwMS, sNfL levels were cross-sectionally associated with walking speed (r = 0.235, q = 0.036), manual dexterity (r = 0.337, q = 0.002), and cognitive processing speed (CPS; r =−0.265, q = 0.012). Baseline sNfL levels predicted 5-year EDSS scores (r = 0.25, q = 0.012), dexterity (r = 0.224, q = 0.033), and CPS (r =−0.205, q = 0.049). CI patients had higher sNfL levels (27.2 vs. 20.6, p = 0.016) and greater absolute longitudinal sNfL increase when compared with non-CI patients (4.8 vs. 0.7, p = 0.04). Higher sNfL levels are associated with poorer current and future clinical and cognitive performance.

13 August 2018 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Dejan JakimovskiDejan Jakimovski
Dejan Jakimovski
SGSirin Gandhi
Sirin Gandhi
IPIvo Paunkoski
Ivo Paunkoski
Niels BergslandNiels Bergsland
Niels Bergsland
JHJesper Hagemeier
Jesper Hagemeier
RZRobert Zivadinov
Robert Zivadinov